RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1

15 Aug, 2018 RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1

On August 15, 2018, we hosted an online RNAi Roundtable to review the progress with lumasiran, an RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1.

Access the replay

View the presentation

Read the transcript

• Pritesh Gandhi, Pharm.D., Vice President, General Manager, Lumasiran
• Richard Riese, M.D., Ph.D., Vice President, Clinical Development
• Sally-Anne Hulton, M.D., FRCPCH, MRCP, FCP, MBBCh, Consultant Paediatric Nephrologist and Clinical Lead, Birmingham Children’s Hospital NHS Trust
• Kim Hollander, Executive Director, Oxalosis & Hyperoxaluria Foundation